Jesse, a patient living with gMG, has received compensationfrom Alexion Pharmaceuticals, Inc.
It is not known if ULTOMIRIS® is safe and effective for the treatment of gMG in children.
Start your adult patients with anti-AChR antibody-positive gMG on ULTOMIRIS® (ravulizumab-cwvz)
Provide a prescription for ULTOMIRIS, order the meningococcal vaccination series, and enroll your patient in support services, all in one place.
- Submitting the form begins OneSource™ enrollment. Once enrollment is complete, OneSource is available to assist with all additional steps
- Submitting online can streamline the onboarding process, but the form can also be submitted via fax or email. Email the completed form to OneSource@Alexion.com or fax to 1-800-420-5150
- OneSource can help arrange meningococcal vaccinations before starting treatment
- Have patients complete or update vaccinations for meningococcal bacteria (serogroups A, C, W, Y, and B) according to ACIP guidelines at least 2 weeks prior to initiating ULTOMIRIS1
- Depending on insurance, infusions may occur at a healthcare professional’s office, an infusion center, or in the patient’s home
- Locate an infusion center convenient for your patients, or contact OneSource for live assistance
AChR, acetylcholine receptor; ACIP, Advisory Committee on Immunization Practices; gMG, generalized myasthenia gravis.
OneSource™ CoPay Assistance
The Alexion OneSource CoPay Program provides financial assistance by covering eligible patients’ out-of-pocket medication and infusion costs associated with ULTOMIRIS.
Please refer to the full Terms and Conditions for additional eligibility requirements.